Order of the National Green Tribunal in the matter of In Re: News Item titled "Nayar river is vanishing - a yatra reveals conservation goes beyond science and policy" appearing in ‘The Down To Earth’ dated 03.06.2025. The original application was registered suo-motu based on the news item titled "Nayar …
IFITM3 is critical for limiting the severity of influenza virus infections in humans and mice. Optimal antiviral activity of IFITM3 is achieved when it is present at high levels within cells. Our results indicate that the E3 ubiquitin ligase NEDD4 decreases baseline IFITM3 levels by ubiquitinating IFITM3 and promoting its …
A nanocapsule that dissolves blood clots very fast and can be administered without specialised equipment promises to be the next revolution in treatment of heart attacks and strokes, says a study. The capsule with the drug can be administered by paramedics in emergency situations saving much time. It acts within …
In 1996, the global HIV community gathered in Vancouver, Canada, for the XI International AIDS Conference and shared the clear evidence that triplecombination antiretroviral treatment held the power to stem the tide of deaths from AIDS. The HIV treatment era had begun. As we gathered again in Vancouver in July, …
The outbreak of Ebola fever in Guinea, Liberia and Sierra Leone, which has killed more than 11,000 people, has dropped out of the news as it has been brought under control. Although new cases are now measured in dozens, rather than hundreds, a week, the disease has not been stamped …
The objective of the study was to investigate the association between use of combined oral contraceptives and risk of venous thromboembolism, taking the type of progestogen into account. Original Source
When Ebola broke out in West Africa in December 2013, triggering the largest-ever epidemic of the disease, there was no vaccine or drug that had been shown to be safe and effective in people. Just 20 months later, a vaccine seems to confer total protection against infection, according to the …
A novel Ebola virus (EBOV) first identified in March 2014 has infected more than 25,000 people in West Africa, resulting in more than 10,000 deaths. Preliminary analyses of genome sequences of 81 EBOV collected from March to June 2014 from Guinea and Sierra Leone suggest that the 2014 EBOV originated …
A new drug compound could lead to a breakthrough in the fight against bovine spongiform encephalopathy, the incurable brain-wasting disease also known as mad cow disease, researchers said Wednesday. Scientists said the new antiprion drug, known as polythiophene, has proven highly effective in mice in blocking toxic, misfolded prions. Prions …
Cern is developing a "mini Large Hadron Collider" to treat cancer through high-intensity beams produced by the 2m-long machine. The miniature linear accelerator (mini-Linac) will consist of four modules, all 50cm long. So far, just the first module has been constructed, said Serge Mathot of the CERN engineering department. The …
Global vaccine-development fund could save thousands of lives, billions of dollars A $2 billion global vaccine-development fund is needed to prevent the world's deadliest infectious diseases, according to an essay published in the New England Journal of Medicine. Credit: Princeton University, Woodrow Wilson School Ebola is a preventable disease, and …
Researchers at the Perelman School of Medicine at the University of Pennsylvania have devised an entirely new approach to vaccines - creating immunity without vaccination. The study, published in Scientific Reports, demonstrated that animals injected with synthetic DNA engineered to encode a specific neutralizing antibody against the dengue virus were …
Washington State University researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism's DNA sequence. Their assertion is a dramatic shift in how we …
Results from a phase-III trial of the vaccine candidate VSV-EBOV has shown the vaccine is highly effective against Ebola, the World Health Organisation has said. It said results from a preliminary trial in Guinea showed "an extremely promising development," according to Dr Margaret Chan, WHO director-general. "The credit goes to …
Retinitis pigmentosa (RP) is a group of inherited retinal degenerations leading to blindness due to photoreceptor loss. Retinitis pigmentosa is a rare disease, affecting only approximately 100 000 people in the United States. There is no cure and no approved medical therapy to slow or reverse RP. The purpose of …
A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine candidate. The researchers report the results of an interim analysis of a trial of rVSV-ZEBOV in Guinea, west Africa.
LONDON – Researchers in the United States trying to develop a vaccine against the deadly Middle East respiratory syndrome (MERS) virus say they have had early signs of success in animal experiments. Using a two-step approach in mice and rhesus macaques, scientists at the vaccine research center of the U.S. …
The human lens is comprised largely of crystallin proteins assembled into a highly ordered, interactive macro-structure essential for lens transparency and refractive index. Any disruption of intra- or inter-protein interactions will alter this delicate structure, exposing hydrophobic surfaces, with consequent protein aggregation and cataract formation. Cataracts are the most common …
The most advanced candidate vaccine against dengue viruses, called CYD-TDV, is progressing toward potential registration and review by the World Health Organization (WHO) in 2016. CYDTDV is a formulation of four chimeric yellow fever 17D vaccine viruses, each one engineered to express the surface envelope and prM (membrane) proteins from …
A candidate tetravalent dengue vaccine is being assessed in three clinical trials involving more than 35,000 children between the ages of 2 and 16 years in Asian–Pacific and Latin American countries. The researchers report the results of long-term follow-up interim analyses and integrated efficacy analyses.
The world's first malaria vaccine has cleared one of the final hurdles prior to being approved for use in Africa. The European Medicines Agency gave a positive scientific opinion after assessing its safety and effectiveness. It represents a 'green light' for the Mosquirix jab, developed by GlaxoSmithKline. The World Health …
